Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine
โ Scribed by Makoto Ishikawa; Futoshi Okada; Jun-Ichi Hamada; Masuo Hosokawa; Hiroshi Kobayashi
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- French
- Weight
- 624 KB
- Volume
- 39
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
โฆ Synopsis
The effect of quercetin, a flavonoid derivative, on the transplantability (tumorigenicity) and metastatic behavior of mouse tumor cells was studied. BMT-I I cl-9 fibrosarcoma cells were treated in vitro with quercetin, and after cloning by limiting dilution, cell suspensions of each clone were injected subcutaneously (s.c.) into syngeneic C57BU6 mice at a dose of 2 x lo5 cells per mouse. Out of 17 clones examined, 8 were nonturnorigenic in normal mice ("regressor" clones), whereas these clones were able to grow in immunosuppressed (600rad-irradiated) mice. Furthermore, I out of 9 tumorigenic clones metastasized spontaneously to the lungs despite the very low metastatic potential of the parent BMT-I I cl-9 cells.
In contrast, all 15 clones selected from the untreated parental line grew progressively in normal mice with no evidence of metastases. The appearance of both regressor and metastatic clones was also observed after treatment with a DNA hypomethylating agent, 5-azacytidine. These altered phenotypes resulting from treatment with both chemicals, however, were not necessarily stable if maintained in culture for several months. The data suggest that quercetin may be a useful new material for obtaining regressor or metastatic clones from parental tumor lines.
๐ SIMILAR VOLUMES
Treatment of a variety of highly tumorigenic mouse lines in vitro with chemical mutagens, such as ethyl methane sulfonate (EMS) or N-methyl-N'-nitro-Nnitrosoguanidine (MNNG), can result in extraordinarily high frequencies (sometimes in excess of 90%) of strongly immunogenic clones unable to grow pro
## Detection of circulating tumor cells in the peripheral blood of patients with androgen-independent, advanced or metastatic prostate cancer To the Editor: The presence of circulating tumor cells (CTC) in the peripheral blood of cancer patients has attracted a great deal of attention among invest